Caroline Kruse

Caroline Kruse
Platelet Disorder Support Association

About

33
Publications
2,757
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
589
Citations
Citations since 2017
32 Research Items
588 Citations
2017201820192020202120222023050100150200
2017201820192020202120222023050100150200
2017201820192020202120222023050100150200
2017201820192020202120222023050100150200
Introduction
Skills and Expertise

Publications

Publications (33)
Article
BACKGROUND AND AIMS Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder causing low platelet counts (PC) and increased bleeding. COVID-19 vaccines are a major concern for ITP patients who fear vaccination might exacerbate their thrombocytopenia. To assess these concerns, PDSA developed a survey to explore how COVID-19 vaccinations impa...
Article
Introduction: Cases of de novo immune thrombocytopenia (ITP), including a fatality following SARS-CoV-2 vaccination in a previously healthy recipient, led to studying its impact in pre-existing ITP. Published reports are limited but suggest that most patients with ITP tolerate the COVID-19 vaccines well without frequent ITP exacerbations (Kuter, BJ...
Article
BACKGROUND AND AIMS Fear of receiving protective vaccinations against the COVID-19 virus is high among patients with immune thrombocytopenia (ITP), an autoimmune bleeding disorder, due to uncertainty around effects on platelet count (PC) reactivity. Decreases in PC have been previously reported, including decreases of >100,000/µL including a need f...
Article
Full-text available
Cases of de novo immune thrombocytopenia (ITP) - including a fatality - following SARS-CoV-2 vaccination in previously healthy recipients led to studying its impact in pre-existing ITP. In this study, four data sources were analyzed: the Vaccine Adverse Events Reporting System (VAERS) for cases of de novo ITP; a ten-center retrospective study of ad...
Article
Full-text available
Immune thrombocytopenia (ITP) has a substantial, multifaceted impact on patients’ health‐related quality of life (HRQoL). Data describing which aspects of ITP physicians and patients perceive as having the greatest impact are limited. ITP World Impact Survey (I‐WISh) was a cross‐sectional survey, including 1507 patients and 472 physicians, to estab...
Article
Full-text available
Immune thrombocytopenia (ITP) is now well‐known to reduce patients' health‐related‐quality‐of‐life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I‐WISh (ITP World Impact Survey) was an exploratory, cross‐sectional...
Article
Full-text available
Background Thrombopoietin receptor agonists (TPO‐RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. Objectives To develop expert consensus on when it is appropriate to consider tapering TPO‐RAs in ITP, how to taper patients off therapy, how to monit...
Article
Full-text available
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet production. First-line therapies include corticosteroids, intravenous immunoglobulin, and anti-D immunoglobulin. For patients who are refractory to these therapies, those...
Article
Background:Immune thrombocytopenia purpura (ITP) is an autoimmune bleeding disorder that is heterogeneous in presentation, disease course, treatment response, and impact on quality of life. Treatments often cause unpleasant side effects, and prolonged use can lead to tolerability issues and toxicity. Disease symptoms and treatments available impact...
Article
Background:Immune thrombocytopenia purpura (ITP) is an autoimmune bleeding disorder that is heterogeneous in presentation, disease course, treatment response, and impact on quality of life. Treatments often cause unpleasant side effects, and prolonged use can lead to tolerability issues and toxicity. Both disease symptoms and treatments available i...
Article
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder defined by a platelet count < 100 × 109/L without explanation, and an increased risk of bleeding. ITP itself as well as its treatments have multifaceted, often poorly understood impacts on patients' quality of life (QoL). These effects include impact on activities of daily living, emo...
Article
Background: Thrombopoietin receptor agonists (TPO-RAs) (e.g., romiplostim, eltrombopag, avatrombopag) are used to stimulate platelet production in patients with primary immune thrombocytopenia (ITP). While it was previously thought that patients would need to remain on a TPO-RA indefinitely, case reports and cohort studies have shown that some pati...
Article
Full-text available
Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An exp...
Article
Treatment strategies for immune thrombocytopenia (ITP) aim to achieve a platelet count associated with adequate hemostasis while maximizing patient (pt) quality of life (QoL) and minimizing treatment-emergent toxicities. However, physicians' (MDs) and pts' treatment goals have not been studied and compared. I-WISh is a cross-sectional survey of 150...
Article
Background: Immune thrombocytopenia (ITP) is an autoimmune disorder causing reduced platelet counts <100,000/µL, with potential bleeding consequences and reduced quality of life. Treatment is generally reserved for adults with platelet counts <30,000/µL. Methods: ITP patients from the Platelet Disorder Support Association were recruited to complete...
Article
Background and Aims Patients with Immune Thrombocytopenia (ITP) may have bleeding because of low platelet counts; many also have reduced quality of life (QoL). Course of therapy can vary by duration and severity of disease but includes steroids and thrombopoietin receptor agonists [TPO-RA]. Both symptoms of ITP and side effects from treatments impa...
Article
Background Although significant advances have been made over the past 10 years in the treatment of Immune Thrombocytopenia (ITP), challenges remain in addressing the burden of disease and unmet needs of patients. In rare diseases especially, natural history studies and patient registries are crucial in establishing baseline information and identify...
Article
Background: The impact of ITP on patient (pt) QoL is multidimensional, broadly encompassing daily activities, emotional health, and work life. Health-related QoL has been shown to be substantially reduced in ITP pts relative to healthy controls, yet the full impact of ITP on affected pts is not well-defined. Aims: I-WISh studied the burden of ITP a...
Article
Background: ITP has a multifaceted impact on patients' (pts) lives but there are limited data on which signs and symptoms treating physicians (MDs) and pts perceive as having the greatest impact, especially on pt quality of life (QoL). As in many chronic autoimmune diseases, fatigue can significantly affect QoL in ITP pts. Aims: I-WISh studied the...
Article
Background: Primary immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impaired platelet production which may result in severe and chronic, symptomatic thrombocytopenia in a considerable minority of patients. The impact of chronic ITP (cITP) on the health-related quality of life (HRQoL), as it occurs in child...

Network

Cited By